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H
ow to screen and treat gestational
diabetesmellitus(GDM)hasalways
been controversial for clinicians
and decision makers. The problem is
complex, and the evidence is limited.
The new standards set by the American
Diabetes Association (ADA) in 2011 (1)
recommend 1) universal screening at
24–28 weeks of gestation (2010 ADA
standardsrecommended selectivescreen-
ing based on risk factors) and 2) an oral
glucose tolerance test with a diagnostic
fasting plasma glucose of $92 mg/dL
(4.5mmol/L) (much lower than the World
Health Organization [WHO] criteria of
$126 mg/dL [7.0 mmol/L] commonly
used in clinical practice in Europe). Fur-
thermore, diabetes is diagnosed when
only one abnormal value is detected
(whereasinthe2010standardstwoabnor-
mal values were needed).
The recommendation is graded as C
(“evidence from poorly controlled or un-
controlled studies”) (1) and is based on
the results of the Hyperglycemia and Ad-
verse Pregnancy Outcome (HAPO) study
(2), a multicentric observational study
that suggests a linear relationship be-
tween GDM risk and glucose level. It is
not clear what led the ADA panel to
change its 2010 recommendations be-
cause the HAPO study fails to identify a
cut off level for plasma glucose predictive
ofanincreasedriskforthemotherandthe
baby, whereas, as recommended by the
UK National Screening Committee (3),
deﬁningaclearthresholdshouldbeapre-
requisite for a screening test. Moreover,
the increasing risk identiﬁed by the study
relates mostly to outcomes that are not
clinically relevant, whereas evidence on
clinically important outcomes is lacking.
Despite this limited evidence, the ADA
issued a recommendation that will cer-
tainly increase the number of women la-
beled as having GDM (17.8% of pregnant
women based on HAPO data).
We believe that the implementation
of the ADA recommendation may give
rise to a number of problems. Firstly, the
clinicalbeneﬁtsfor women andbabiesare
unclear. A recent systematic review (4)
suggests that the clinical beneﬁts of treat-
ing GDM, diagnosed according to the
WHO criteria, are modest and limited
only to not primary outcomes (shoulder
dystocia) even when intensive treatment
is provided. By adopting a lower diagnos-
tic threshold it is likely that the beneﬁts
will be even smaller. Secondly, pregnant
women diagnosed as having GDM that
will not reach normal glycemic values
afterlifestylemodiﬁcationsmightbetreated
w i t hi n s u l i n .H o wm a n yh y p o g l y c e m i c
episodes are acceptable to be conﬁdent
that we are doing more good than harm
by adopting the new screening strategy?
Finally, the universal screening might
represent a signiﬁcant burden for health
systems, considering that the current
practice does not imply an oral glucose
tolerance test in every pregnant women.
On the basis of the above considerations,
the newly published Italian guidelines on
antenatalcareforhealthypregnantwomen
(5), developed by means of the GRADE
methodology for evidence assessment
(www.gradeworkinggroup.org), recom-
mend screening for GDM only in women
at increased risk by means of the WHO
diagnostic criteria. GDM surely requires
a prompt diagnosis. Nevertheless, an
evidence-based appraisal of the available
evidence—balancing beneﬁts and harms,
feasibility, resource use, and burden of a
universalscreening—seems not to support
the 2011 ADA recommendations.
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